These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12355959)

  • 1. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Isurugi K; Niijima T; Aso Y; Araki T
    Hinyokika Kiyo; 1988 Feb; 34(2):369-82. PubMed ID: 2967622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
    Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
    Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
    Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endocrine therapy for prostate cancer in the future].
    Usami M
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
    Zinner NR; Bidair M; Centeno A; Tomera K
    Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.